The U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) to begin the development of Aristada, a long-acting injectable unusual antipsychotic, to treat schizophrenia in adults. The move will now make it possible to dose patients with Aristada Initio in combination with a single 30 mg dose of oral aripiprazole as an alternative to begin prescribing any dose of Aristada on the very first day of the treatment of the mental disorder, the manufacturer announced in a press release. It would also be possible to provide patients with the relevant levels of aripiprazole within the four days of initiation. The medication is expected to be available by mid-July.
Until now, it was challenging for patients to transition from inpatient care to outpatient settings. Medical compliance and continuity of care was also not easy. Moreover, the initiation schedule for Aristada used to begin with its first dose and included 21 consecutive days of oral aripiprazole. But with the new development, an alternative treatment option for individuals with schizophrenia has been made available. Aristada Initio can be used onto any dose of Aristada to begin the treatment process. This, in turn, would offer patients and health care providers a flexible treatment option as it would allow administering the first Aristada dose on the same day as Aristada Initio or up to 10 days thereafter.
Dr. David Walling, chief executive officer and principal investigator of the Collaborative Neuroscience Network, said that the new Aristada Initio regimen would make it possible for patients to recover within two months of undergoing treatment while also allowing the care team to focus their efforts on other important aspects of the long-term positive outcomes.
Treatment providers cannot exchange Aristada Initio with Aristada
Though both Aristada Initio and Aristada contain aripiprazole lauroxil, it is neither possible nor recommended to exchange one with another. This is because both these drugs have different pharmacokinetic profiles. Compared to Aristada, Aristada Initio uses NanoCrystal technology and has been designed in a way that enables it to provide an extended-release formulation using a smaller particle size of aripiprazole lauroxil. This, in turn, allows for quicker dissolution as well as leads to a faster achievement of relevant aripiprazole levels.
A ray of hope
According to the Schizophrenia and Related Disorders Alliance of America (SARDAA), approximately 3.5 million people in the country are diagnosed with the condition. Several studies conducted in the past indicated that 25 percent of individuals with schizophrenia recover completely, while 50 percent are able to show signs of improvement over a period of 10 years.
Characterized by disruptions in thought processes, perceptions, emotional responsiveness, and social interactions, the condition can be identified if one displays the presence of symptoms like hallucinations, delusions, reduced expression of emotions, lowered motivation to accomplish goals and cognitive impairment. If you know someone displaying any such signs and is looking for one of the best residential treatment centers for schizophrenia, Sovereign Health can help. We are one of the best rehabs in the U.S. offering comprehensive treatment for various forms of mental illnesses, including schizophrenia. For complete details about our state-of-the-art schizophrenia treatment centers located in different parts of the U.S., call us at our 24/7 helpline or chat online with one of our representatives who are available to assist you with the required information.